Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Shares Outstanding (Diluted Average) (2017 - 2026)

Champions Oncology has reported Shares Outstanding (Diluted Average) over the past 14 years, most recently at $13.8 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) fell 3.89% year-over-year to $13.8 million; the TTM value through Jan 2026 reached $13.8 million, down 3.89%, while the annual FY2025 figure was $14.3 million, 5.31% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $13.8 million at Champions Oncology, roughly flat from $13.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $14.4 million in Q1 2022 and troughed at $13.5 million in Q3 2023.
  • A 5-year average of $13.8 million and a median of $13.8 million in 2025 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): decreased 5.76% in 2023 and later grew 5.67% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $13.5 million in 2022, then rose by 0.01% to $13.5 million in 2023, then increased by 3.7% to $14.0 million in 2024, then dropped by 1.93% to $13.8 million in 2025, then increased by 0.34% to $13.8 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CSBR at $13.8 million in Q1 2026, $13.8 million in Q4 2025, and $13.8 million in Q3 2025.